September 9, 2016 09:35 AM EDT
Bioregnum
Opinion

Thumbs Up/Down: Brent Saun­ders has the right idea on drug pric­ing, let's sup­port that

End­points as­sess­es the big bio­phar­ma R&D sto­ries of the week, with a lit­tle added com­men­tary on what they mean for the in­dus­try.

Brent Saun­ders …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

Judge halts some NIH cuts af­ter 22 states sue

Ver­tex op­er­a­tions chief Stu­art Ar­buck­le to re­tire

Mer­ck KGaA con­firms in­ter­est in ac­quir­ing can­cer biotech Spring­Works

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times